CN106083788B - A kind of quinoid chalcone carbon glycosides dimer compound with antitumor activity and anti-inflammatory activity and preparation method thereof - Google Patents

Abstract

The invention discloses a quinone-type chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity and a preparation method thereof. The present invention conducts systematic and in-depth research on the chemical components of safflower, and through spectral and mass spectrometry data analysis shows that a new compound (formula II) is isolated from safflower, and the quinone ring isolated for the first time is 1,5-cyclohexadiene A quinone chalcone carbon glycoside dimer compound of ketone. Anti-inflammatory and anti-tumor activity studies have shown that the quinoidal chalcone carbon glycoside dimer compound provided by the present invention has good anti-inflammatory activity, and can inhibit DNA topoisomerase I, and has great anti-inflammatory effects on various tumors. Strong anti-tumor activity, and through toxicity experiment research shows, the quinochalcone and flavonol conjugates with anti-tumor activity and anti-inflammatory activity provided by the present invention have low toxicity, and can be developed into new anti-tumor drugs or anti-tumor drugs. Inflammatory drugs have important application value.

Description

Dimerization of a quinoidal chalcone carboglycoside with antitumor and anti-inflammatory activities compound and its preparation method

technical field

The present invention relates to a compound with antitumor activity, in particular to a new compound of quinone chalcone carbon glycoside dimer compound extracted from the traditional Chinese medicine safflower with antitumor activity and anti-inflammatory activity and its role in the prevention and treatment of tumors The use in diseases and inflammatory diseases belongs to the technical field of medicine.

Background technique

Safflower is the dried flower of Carthamus tinctorius L., a plant of Compositae. It was first recorded in "Kaibao Materia Medica". It is mainly produced in Xinjiang, Henan, Zhejiang, Yunnan and other places. The effect of promoting menstrual flow, dispelling blood stasis and relieving pain has been used as a traditional Chinese medicine for promoting blood circulation and removing blood stasis to treat stroke, coronary heart disease and angina pectoris for more than 2,500 years. The safflower injection made from the water extract of safflower is recorded in the twenty volumes of Chinese medicine prescriptions prepared by the Ministry of Health, and is widely used clinically for the treatment of cardiovascular diseases. At present, more than 200 compounds have been isolated from safflower, including quinone chalcone glycosides, flavonoids, alkaloids, organic acids and steroids, etc., and quinone chalcone glycosides are safflower water The main components of the extract, such as hydroxyl safflower yellow A (HSYA), safflower yellow A, safflomin C and dehydrated safflower yellow B (AHSYB). Modern pharmacological research has found that safflower and its active ingredients have anti-coagulation, anti-oxidation, anti-inflammatory, liver protection, and antihypertensive activities.

The present invention continues to systematically study the chemical components of the safflower, systematically separates the quinone chalcone glycosides in the water part, and researches and develops its new active structure.

Contents of the invention

Purpose of the invention: The purpose of the invention is to systematically study the chemical components of safflower on the basis of the prior art, systematically separate the quinone chalcone glycosides in the water part, and research and develop new active structures , and screen its new application in the prevention and treatment of tumor diseases, inflammatory diseases and antithrombotic diseases through pharmacological experiments.

Technical scheme: in order to realize above object, the technical scheme that the present invention takes is:

A quinone-type chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity, its structural formula is shown in formula II:

.

The preparation method of the quinoid chalcone carbon glycoside dimer compound with antitumor activity and anti-inflammatory activity comprises the following steps:

(1) Get the safflower, add ethanol to extract to obtain the ethanol extract, combine the extract, concentrate, and obtain the ethanol extract;

(2) Get the ethanol extract prepared in step (1), extract with sherwood oil, ethyl acetate and water successively, concentrate after extraction, obtain the extract of sherwood oil, ethyl acetate and water respectively;

(3) get the extract of the water that step (2) obtains, go up the macroporous adsorption resin column, water elution earlier, be 5～95% ethanol elution with volume concentration respectively then, collect the ethanol that volume concentration is 30% The eluent is concentrated to obtain the eluate of the macroporous adsorption resin;

(4) LH-20 gel column chromatography on the macroporous adsorption resin eluate obtained in step (3), the eluent is H ₂ O-MeOH (volume ratio is from 100:0 to 0:100), Get 30 fractions;

(5) Take the eluate from the LH-20 gel column in step (4) and separate it by pre-HPLC chromatography to obtain the quinone chalcone carbon glycoside dimer compound shown in formula II.

As a preferred option, the preparation method of the above quinoidal chalcone carbon glycoside dimer compound with antitumor activity and anti-inflammatory activity, the extraction method of step (1) is percolation method, ultrasonic extraction method, soaking method or reflux method .

As a preferred option, the preparation method of the above-mentioned quinoidal chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity, the separation condition of step (5) pre-HPLC chromatographic separation: XBridge ^TM C18OBD ^TM column (150×30mm, 5μm), the mobile phase is 0.1% formic acid water (A) and methanol (B), using a gradient elution program: 0-5min, 16%-19%B; 5-15min, 19%B; 15 -20min, 19%-44%B; 20-30min, 44%B; 30-32min, 44%-100%B. The flow rate was 15 mL/min; the column temperature was room temperature (25° C.).

Application of the quinoidal chalcone carbon glycoside dimer compound having antitumor activity and antiinflammatory activity in the preparation of antiinflammatory drugs.

As another preferred solution, the application of the quinoidal chalcone carbon glycoside dimer compound having anti-tumor activity and anti-inflammatory activity in the preparation of anti-thrombotic diseases.

As another preferred solution, the application of the quinochalcone carbon glycoside dimer compound having anti-tumor activity and anti-inflammatory activity described in the present invention in the preparation of anti-tumor drugs. The tumor is lung cancer, stomach cancer, colon cancer, cervical cancer, breast cancer, liver cancer or kidney cancer.

The quinone-type chalcone carbon-glycoside dimer compound having anti-tumor activity and anti-inflammatory activity of the present invention is prepared into a tablet by preparing the quinone-type chalcone carbon-glycoside dimer compound compound and a pharmaceutically acceptable carrier , capsules, injections, powder injections, granules, microcapsules, pills, ointments or transdermal controlled-release patches.

When the quinoidal chalcone carbon glycoside dimer compound provided by the present invention is made into a tablet, the quinoid chalcone carbon glycoside dimer compound and lactose or cornstarch are added if necessary, and lubricant magnesium stearate is added, Mix evenly, granulate, and then compress into tablets.

When the quinone-chalcone carbon glycoside dimer compound provided by the present invention is made into capsules, the quinone-chalcone carbon glycoside dimer compound and the carrier lactose or cornstarch are mixed evenly, granulated, and then encapsulated to make a capsule agent.

When the quinone chalcone carbon glycoside dimer compound provided by the present invention is made into granules, the quinone chalcone carbon glycoside dimer compound and the diluent lactose or cornstarch are mixed evenly, granulated, dried, and prepared into granules.

The quinone chalcone carbon glycoside dimer compound provided by the invention is prepared by adding a carrier when making a powder injection or an injection according to a conventional pharmaceutical method.

The quinone chalcone carbon glycoside dimer compound provided by the present invention is prepared by adding a carrier when it is made into fat emulsion, ointment or transdermal controlled-release patch and other dosage forms according to conventional pharmaceutical methods.

Beneficial effects: Compared with the prior art, the quinoidal chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity has the following advantages:

The present invention conducts systematic and in-depth research on the chemical components of safflower, and analyzes the spectral and mass spectrometry data to show that chalcones are isolated from safflower. The compound shown in formula II is the first isolated quinone ring of 1,5- The quinone-type chalcone carbon glycoside dimer of cyclohexadienone is a compound with a new skeleton structure. And through anti-inflammatory and anti-tumor activity studies show that the quinoidal chalcone carbon glycoside dimer compound provided by the present invention has good anti-inflammatory activity, and can inhibit DNA topoisomerase I, and has anti-inflammatory effects on various tumors. Strong anti-tumor activity, and toxicity experiments show that the quinone chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity provided by the present invention has low toxicity and can be developed into a new anti-tumor drug Or anti-inflammatory drugs, has important application value.

The preparation method provided by the invention has reasonable process design and strong operability, and the prepared quinone chalcone carbon glycoside dimer compound has high purity.

Description of drawings

Fig. 1 is the structural representation of quinone type chalcone carbon glycoside dimer compound formula II;

Fig. 2 is the ¹ H-NMR figure of quinone type chalcone carbon glycoside dimer compound formula II;

Fig. 3 is the ¹³ C NMR chart of the quinone chalcone carbon glycoside dimer compound formula II.

Detailed ways

The present invention can be better understood from the following examples. However, those skilled in the art will readily understand that the specific material ratios, process conditions and results described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims .

Embodiment 1 Preparation of quinone chalcone carbon glycoside dimer compound

The preparation method of the quinoid chalcone carbon glycoside dimer compound with antitumor activity and anti-inflammatory activity comprises the following steps:

(1) Get 15kg of safflower, add successively 95% and 70% ethanol percolation extraction to colorless, obtain ethanol extract, combine extract, concentrate, get ethanol extract 1950g;

(2) Get the ethanol extract prepared in step (1), disperse it in water, extract with sherwood oil and ethyl acetate successively, concentrate after extraction, obtain the extract of sherwood oil, ethyl acetate and water respectively;

(3) Get the extract of the water that step (2) obtains, go up D101 macroporous adsorption resin column, water elution first, then use the ethanol elution that volume concentration is 5～95% respectively, collection volume concentration is 30% The ethanol eluent was concentrated to obtain the eluate of the macroporous adsorption resin;

(4) LH-20 gel column chromatography on the macroporous adsorption resin eluate obtained in step (3), the eluent is H ₂ O-MeOH (volume ratio is from 100:0 to 0:100), Get 30 fractions;

(5) Take the 9th fraction and the 3rd fraction of the eluted fraction of the LH-20 gel column in step (4), and separate them on pre-HPLC chromatography. The separation condition of pre-HPLC chromatographic separation: XBridge ^TM C18OBD ^TM column (150×30mm, 5μm), the mobile phase is 0.1% formic acid water (A) and methanol (B), using a gradient elution program: 0-5min, 16%-19%B; 5-15min, 19%B; 15 -20min, 19%-44%B; 20-30min, 44%B; 30-32min, 44%-100%B. The flow rate was 15 mL/min; the column temperature was room temperature (25° C.).

The quinone chalcone carbon glycoside dimer compound represented by formula II is obtained, and the structural formula is shown in Fig. 1 .

Formula II shows:

The structural analysis of formula II is: dark orange powder, [α] _D ²⁰ : +134.7 (c 0.1, MeOH). High-resolution mass spectrometry (HR-ESI-MS: m/z=1043.2679[MH] ^-1 , calcd.1043.2674) showed that its molecular formula was C ₄₈ H ₅₁ O ₂₆ . The strong absorption of infrared spectrum at 3433cm ^-1 shows that it has hydroxyl group, the characteristic absorption of carbonyl group also appears at 1640cm ^-1 , and the characteristic absorption of aromatic ring also appears at 1513 and 1400cm ^-1 . The ultraviolet spectrum shows that there are maximum absorptions at 228, 344 and 420nm, indicating that there is a highly conjugated system in the molecule.

¹ H-NMR (Fig. 2) showed that two sets of p-hydroxycinnamoyl signals were δ7.51 (1H, d, J = 16.0Hz), 7.19 (1H, d, J = 16.0Hz), 7.39 (2H, d, J=8.5Hz), 6.76(2H,d,J=8.5Hz), 9.70(1H,br s), and δ7.45(1H,d,J=16.0Hz), 7.16(1H,d,J=16.0 Hz), 7.37 (2H, d, J = 8.5 Hz), 6.76 (2H, d, J = 8.5 Hz). In addition, in ¹ H-NMR, there are two carboside glucose terminal hydrogen signals δ3.78 (1H, d, J = 9.0Hz) and 3.57 (1H, d, J = 9.5Hz), a deoxysorbitol terminal The base hydrogen signal δ4.56 (1H, d, J = 8.0Hz), and some glycan hydrogen signal δ2.9-4.6ppm.

¹³ C-NMR (Fig. 3) shows that there are 48 carbon atoms, combined with ¹ H-NMR, HSQC and accurate molecular weight, it can be determined that the compound is an isomer of AHSYB. Likewise, on the MS/MS spectrum, this compound fragments to yield m/z 1025.25[MHH ₂ O] ^- , 923.22 [MHC ₈ H ₈ O] ^- , 593.15 [MHC ₂₁ H ₂₂ O ₁₁ ] ^- and 449.11 [MHC ₂₇ H ₃₀ O ₁₅ ] ^- , consistent with the characteristic fragments of AHSYB cleavage.

On the HMBC spectrum, the correlation of H-2"" and C-1 indicates that OH-2"" and C-1 phenolic hydroxyl form an ester bond. The phenolic hydroxyl hydrogen signal δ18.31 correlates with C-1′(181.5), C-2′(106.0) and C-6′(101.4) HMBC, indicating that the compound exists in the form of 1-enol-3,7-dione . Both quinone rings of this compound exist in the form of 1,5-cyclohexadienone.

The compound exhibits a negative cotton effect at 272nm, indicating that the absolute configurations of both 4 and 4' are S. According to the biogenic synthesis pathway, sorbitan is derived from D-glucose, and the coupling constant of its terminal group proton is 8.0 Hz. Sorbitan is determined to be 1-anhydro D-sorbitol, and the absolute configuration of 1″ is S .

Example 2 Inhibition of LPS-induced activity screening of HUVEC cell inflammatory response

The essence of blood stasis syndrome is microcirculation disturbance or abnormal blood rheology. With the in-depth study of cell and molecular biology, the inflammatory response is closely related to blood stasis syndrome, and a series of inflammatory cells and inflammatory factors participate in the disease process of blood stasis syndrome. Therefore, in this experiment, LPS was used to induce HUVEC to establish an in vitro cell inflammatory response model to evaluate the anti-inflammatory activity of quinone chalcone glycosides.

1. Experimental materials

1.1 Instrument

SERIES II WATER JAVKET _CO2 incubator (Thermo, USA); 1300SERIES A2 biological safety cabinet (Thermo, USA); BWS-10 water bath (Kunshan Yiheng Instrument Co., Ltd.); TOMY SX-500 high-pressure steam sterilization Pot (Queensland Company, Japan); EPED ultrapure water system (Nanjing Yipu Yida Technology Development Co., Ltd.); CKX31SF inverted microscope (OLYMPUS Company); Allegra X-12R general desktop centrifuge (BECKMAN Company, USA); 6-well culture plate (Costar, USA); WGL-230B electric blast drying oven (Tianjin Test Instrument Co., Ltd.); qPCR instrument (Applied Biosystem, USA); ultra-trace nucleic acid protein detector (Queensland, Japan).

1.2 Cells and reagents

HUVEC cells were purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.; high-glucose DEME medium and fetal bovine serum (FBS) were purchased from Gibco, USA; lipopolysaccharide (LPS) was purchased from Sigma-Aldrich, USA; TRIzol reagent was purchased from USA Invitrogen; PrimeScript ^TM RT reagent kit was purchased from TaKaRa Company in Dalian, China.

2. Experimental method

2.1 Cell culture

HUVEC cells were cultured in DMEM medium containing 10% fetal bovine serum, 100mg·mL ^-1 penicillin, and 100mg·mL ^-1 streptomycin in a 37°C, 5% carbon dioxide incubator. Replace the culture medium every 2-3 days, and subculture once every 3-4 days.

2.2 Cell processing and grouping

HUVEC cells were inoculated in a six-well plate at 1× ¹⁰⁵ ·mL ^-1 , with a full volume of 2 mL per well. The experiment was divided into 3 groups: blank group, no LPS and drugs were added; model group, LPS was added, the final concentration was 10 μg·mL ^-1 , no drugs were added; drug administration group: the compounds of the above formula Ⅱ were added sequentially to make the formula Ⅱ-1 The concentration of the compound is 0.8 μmol·L ^-1 , the concentration of the compound of formula II-2 is 4 μmol·L ^-1 , the concentration of the compound of formula II-3 is 20 μmol·L ^-1 , and the concentration of compound II-4 is 100 μmol·L ^-1 drug. After 2 days of continuous administration, the cells were collected for extraction of total RNA.

2.3 RNA extraction

Add 500μL RNAzol to each well of the 6-well plate, prepare 1.5mL bullet, mark it well, scrape the cell HUVEC carefully with a scraper and transfer it to a 1.5mL EP tube; add 500μL DEPC H ₂ O, suspend 15s; centrifuge (13200rpm, 10min, 4°C); take 1000μL of the supernatant into a new EP tube, centrifuge (13200rpm, 30min, 4°C); observe the RNA morphology, pour out the upper liquid, add 500μL 70 to each EP tube % ethanol, centrifuge (13200rpm, 10min, 4°C); repeat once, invert, after drying, add 20μL of 55°C DEPC H ₂ O to each, store at -80°C; measure RNA content by Nano drop (A260/280 in the range of 1.8-2.0).

2.4 Transfer cDNA

TaKaRa kit: PrimeScript ^TM RT reagent Kit with gDNA Eraser

1) Genomic DNA removal reaction

2) Reverse transcription reaction

Store at 4°C;

3) Nano drop was used to measure the cDNA content (the range of A260/280 was 1.6-1.8).

2.6.1.2.5qRT-PCR SYBR Green Kit (QIAGEN)

1) Preparation of qPCR reaction system

2) qPCR reaction program setting

Take HUVEC in the logarithmic growth phase, add a certain concentration of drugs, use the RNAzol one-step method to extract total RNA, and reverse transcribe 1 μg of total RNA in 10 μL system to prepare cDNA and perform reverse transcription PCR. Use primers as follows:

3. Experimental results

Table 1 Formula II quinone chalcone glycoside compound inhibits the expression of inflammatory factors in HUVEC cells induced by LPS

Compared with blank group, ^# P<0.05, ^## P<0.01, compared with model group, ^* P<0.05, ^** P<0.01.

The above experimental results in Table 1 show that the quinone-chalcone carbon glycoside dimer compound of the formula II significantly up-regulates the gene expression of the anti-inflammatory factor IL-10, and the quinone-chalcone carbon glycoside dimer compound of the formula II can be dose-dependent. Tolerantly inhibit the gene expression of IL-1, IL-6 and IFN-γ, the quinone-type chalcone carbon glycoside dimer compound of formula II has a significant inhibitory effect on the gene expression of TNF-α only at high dose concentrations, further It shows that the quinone chalcone carbon glycoside dimer compound has specific anti-inflammatory activity and has the potential to be developed into a new generation of anti-inflammatory drugs.

Example 3 Inhibits the Activity Screening of DNA Topoisomerase I

DNA topoisomerase (Topoisomerase) is an important ribozyme involved in important life activities such as DNA replication, transcription, recombination, gene regulation and cell mitosis. It can control its topology by catalyzing the breakage and combination of DNA strands. In tumor cells, the content and activity of Topo I are much higher than those in normal somatic cells, inhibiting the dissociation of Topo I-DNA cleavable complexes can selectively inhibit the rapid proliferation of tumor cells, and then kill tumor cells ^[8] . Topo I has thus become a recognized target of anticancer drugs. Therefore, in this experiment, the model of inhibiting DNATopo I in vitro was used to evaluate the antitumor activity of quinone chalcone carbon glycoside dimer compounds.

1. Experimental materials

1.1 Instrument

Gel imager (Shanghai Peiqing Technology Co., Ltd.), electrophoresis instrument (Beijing Liuyi Instrument Factory), metal bath (Hangzhou Bioer Technology Co., Ltd.).

1.2 Drugs and reagents

DNATopo I, ρBR322DNA, Agarose Regular, 6×Loading Buffer, and Tris-Borate-EDTABuffer (TBE) powder were purchased from Treasure Bio (Dalian) Co., Ltd.; 10-hydroxycamptothecin (OPT) and sodium lauryl sulfate were purchased from From Shanghai Aladdin Biochemical Technology Company; Super green I was purchased from Beijing Fanbo Biochemical Co., Ltd. The quinone-chalcone carbon glycoside dimer compound of formula II prepared in Example 1.

2. Experimental method

The test uses a 20μL reaction system, including 10×Topo I buffer (350mM Tris-HCl pH8.0, 720mM KCI, 50mM MgCl ₂ , 50mM DTT, 50mM spermidine), 0.1% BSA, 0.5μg calf thymus rhoBR322DNA, 1U Topo 1, the DMSO solution of test compound, positive drug is 10-hydroxycamptothecin (OPT). Place in a metal bath at 37° C. for 30 min, and add 5 μL of reaction termination solution 1.5% sodium dodecyl sulfate (SDS) to terminate the reaction. 1 μL of the product was mixed with 2 μL of 6×loading buffer, loaded on 1% agarose gel, TBE buffer, 90V voltage, and electrophoresed for 60 min. Sybrgreen I was stained for 30 minutes, the results were observed with a gel imager, and photographed and recorded. Enzyme activity unit definition: the amount of Topo I enzyme required to relax 0.5 μg of negatively supercoiled ρBR322 DNA at 37°C for 30 minutes is 1 unit (U).

3. Experimental results

The compound of formula II has obvious inhibitory effect on Topo I at 100 μM, and the result shows that the quinoidal chalcone carbon glycoside dimer has good antitumor activity.

Example 4 In vitro anti-tumor experiment

The present invention uses the improved MTT method to conduct in vitro anti-tumor cell experiments on the quinone-chalcone carbon glycoside dimer compound prepared in Example 1 of the present invention: lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or Kidney cancer was digested with trypsin, counted, and prepared into a cell suspension with a concentration of 5×10 ⁴ cells/ml. Add 100 μl of cell suspension (5×10 ³ cells per well) to each well of a 96-well plate, and then place it in a 37°C, 5% CO ₂ incubator for 24 hours; dilute formula II quinone with incomplete medium Chalcone glycoside compounds to the required gradient concentrations, add 100 μL of the corresponding drug-containing medium to each well, and set up a negative control group, a vehicle control group and a positive control group at the same time, and then place the 96-well plate at 37 ° C, 5% Incubate for 72 hours in a CO ₂ incubator. Then add 20 μL MTT (5 mg/ml) to each well, continue to cultivate for 4 hours, terminate the culture, discard the medium, add 150 μL DMSO to each well to dissolve, and shake gently for 10 minutes to mix well. Use a microplate reader to detect the absorbance or OD value of each well at two wavelengths of λ=4570nm and 620nm, and use the average value of each multiple well as the OD value of the group of cells to calculate the inhibition rate of each drug.

The experimental results show that the quinone-type chalcone carbon glycoside dimer compound of formula II prepared in Example 1 of the present invention has a strong inhibitory effect on lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or kidney cancer , at a dose of 10 μg/ml, the inhibition rates for lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or kidney cancer are all greater than 50%.

The above embodiments are only to illustrate the technical concept and characteristics of the present invention. All equivalent changes or modifications should fall within the protection scope of the present invention.

Claims (5)

1. A quinone-type chalcone carbon glycoside dimer compound with anti-tumor activity and anti-inflammatory activity, characterized in that its structural formula is as shown in formula II: . 2. the preparation method of the quinoidal chalcone carbon glycoside dimer compound with antitumor activity and anti-inflammatory activity according to claim 1, is characterized in that, comprises the following steps: (1) Get safflower, add ethanol percolation and extract to obtain ethanol extract, combine extract, concentrate to obtain ethanol extract; (2) Get the ethanol extract prepared in step (1), disperse it in water, extract with sherwood oil and ethyl acetate successively, concentrate after extraction, obtain the extract of sherwood oil, ethyl acetate and water respectively; (3) Get the extract of the water that step (2) obtains, go up D101 macroporous adsorption resin column, water elution first, then use the ethanol elution that volume concentration is 5～95% respectively, collection volume concentration is 30% The ethanol eluent was concentrated to obtain the eluate of the macroporous adsorption resin; (4) LH-20 gel column chromatography on the macroporous adsorption resin eluate obtained in step (3), the eluent is H ₂ O-MeOH, and the volume ratio is from 100:0 to 0:100, to obtain 30 fractions; (5) Take the eluted fraction of the LH-20 gel column in step (4), and separate it by pre-HPLC chromatography to obtain the quinone chalcone carbon glycoside dimer compound shown in formula II; Separation conditions for pre-HPLC chromatographic separation: XBridge ^TM C18 OBD ^TM column, size 150×30mm, 5μm, mobile phase A is 0.1% formic acid water and B phase is methanol, using gradient elution program: 0-5min, 16 %-19%B; 5-15min, 19%B; 15-20min, 19%-44%B; 20-30min, 44%B; 30-32min, 44%-100%B; the flow rate is 15mL/min; The column temperature was 25°C. 3. The application of the quinoidal chalcone carbon glycoside dimer compound having antitumor activity and anti-inflammatory activity according to claim 1 in the preparation of anti-inflammatory drugs. 4. The application of the quinoidal chalcone carbon glycoside dimer compound having antitumor activity and antiinflammatory activity according to claim 1 in the preparation of antithrombotic diseases. 5. the application of the quinoid chalcone carbon glycoside dimer compound with antitumor activity and anti-inflammatory activity in the preparation of antitumor drugs according to claim 1; the tumor is lung cancer, gastric cancer, colon cancer, cervical cancer cancer, breast cancer, liver cancer or kidney cancer.